Recombinant Rat IL7R cell lysate

• Cat.No.: IL7R-959RCL
• Product Overview: Rat IL7R / IL7RA derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Human cells
• Species: Rat
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.
• Tag: Non

Gene Information

• Gene Name: Il7r interleukin 7 receptor [ Rattus norvegicus ]
• Official Symbol: IL7R
• Synonyms: IL7R; interleukin 7 receptor; interleukin-7 receptor subunit alpha
• Gene ID: 294797
• mRNA Refseq: NM_001106418
• Protein Refseq: NP_001099888
• Pathway: Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Hematopoietic cell lineage, organism-specific biosystem; Hematopoietic cell lineage, conserved biosystem; IL-7 Signaling Pathway, organism-specific biosystem; Jak-STAT signaling pathway, organism-specific biosystem; Jak-STAT signaling pathway, conserved biosystem
• Function: cytokine receptor activity; molecular_function; receptor activity

Reviews

02/21/2022

The pharmacodynamic parameters of IL7R were good.

02/01/2022

IL7R has good compatibility and stability with various excipients.

09/30/2021

Strong potential to desensitize specific allergens.

Q&As

What is the prospect of recombinant IL7R in tumor immunotherapy?

IL7R is a potential drug for tumor immunotherapy, which is expected to enhance anti-tumor immune response, but further research and clinical demonstration are still needed.

Is there any research showing that recombinant IL7R can be used to treat immune system failure?

Recombinant IL7R can enhance the body's immune response, but there is not enough evidence to show that it can be used to treat immune system failure.

How the role of IL7R in immunotherapy?

It can enhance the immune response ability of T cells and improve the immune response of the body, so as to have a therapeutic effect on immune-related diseases.

Does IL7R have synergistic effects with immune checkpoint inhibitors?

There is no clear evidence that IL7R has a synergistic effect with immune checkpoint inhibitors, but this research direction deserves further exploration.

Which diseases is IL7R associated with?

IL7R has been associated with immune-related diseases such as cancer, inflammatory bowel disease, and rheumatoid arthritis.

Is there any restriction on the use of IL7R?

The use of IL7R is patient specific and may be subject to some limitations, such as pregnant and lactating women and patients with certain immune-related diseases.